A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy
and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292
and lenalidomide combination therapy. Subjects will be followed for disease progression and
collection of second primary malignancy (SPM) events. This dose escalation will be followed
by an exploratory expansion phase in 3 cohorts of 12 patients each.